G1 Therapeutics Stock Options
| GTHX Stock | USD 4.11 0.06 1.44% |
G1 Therapeutics' option chain provides insight into all available option contracts written on G1 Therapeutics' stock. Investors can see outstanding put and call contracts with pricing information and greeks for a given expiration period. In addition, each of G1 Therapeutics' stock options below provides a detailed picture of the payoff. Comparing vital and dynamic information of various option contracts across diverse expiration periods will help you make an educated decision on your market timing strategies around investing in a given GTHX option contract.
In The Money vs. Out of Money Option Contracts on G1 Therapeutics
Analyzing G1 Therapeutics' in-the-money options over time can help investors to take a profitable long position in G1 Therapeutics regardless of its overall volatility. This is especially true when G1 Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money G1 Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with G1 Therapeutics' stock while costing only a fraction of its price.
G1 Therapeutics' latest option contracts expiring on 2024-04-19 are carrying combined implied volatility of 305.47 with a put-to-call open interest ratio of 0.17 over 24 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on 2024-04-19. The current put volume is at 3, with calls trading at the volume of 41. This yields a 0.07 put-to-call volume ratio. The G1 Therapeutics option chain provides detailed quote and price information for the current G1 Therapeutics option contracts. It shows all of G1 Therapeutics' listed puts, calls, expiration dates, strike prices, and other pricing information.
Open Interest Against 2024-04-19 Option Contracts
G1 Therapeutics option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in G1 Therapeutics' lending market. For example, when G1 Therapeutics' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on G1 Therapeutics, he or she must hedge the risk by shorting G1 Therapeutics stock over its option's life.
2024-04-19
The chart above shows G1 Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. G1 Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for G1 Therapeutics' option, there is no secondary market available for investors to trade.
G1 Therapeutics' stock options are financial instruments that give investors the right to buy or sell shares of G1 Therapeutics common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell GTHX stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If G1 Therapeutics' stock price goes up or down, the stock options follow.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in G1 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Please note that buying 'in-the-money' options on G1 Therapeutics lessens the impact of time decay, as they carry both intrinsic and time value. So, even if G1 Therapeutics' value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money G1 Therapeutics contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if GTHX Stock moves the wrong way.
At this time, G1 Therapeutics' Total Stockholder Equity is fairly stable compared to the past year. Other Stockholder Equity is likely to rise to about 856.1 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 33.7 M in 2024. G1 Therapeutics In The Money Call Balance
When G1 Therapeutics' strike price is surpassing the current stock price, the option contract against G1 Therapeutics stock is said to be in the money. When it comes to buying G1 Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on G1 Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
GTHX Current Options Market Mood
G1 Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps GTHX Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Most options investors, including buyers and sellers of G1 Therapeutics' calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. G1 Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction. Using current G1 Therapeutics' option volume and open interest to make an investment decision is considered a contrarian-sentiment measure that can be utilized in many timing strategies in both derivative and spot marketplace.
Rule 16 of the current GTHX contract
Base on the Rule 16, the options market is currently suggesting that G1 Therapeutics will have an average daily up or down price movement of about 19.09% per day over the life of the 2024-04-19 option contract. With G1 Therapeutics trading at USD 4.11, that is roughly USD 0.78. If you think that the market is fully incorporating G1 Therapeutics' daily price movement you should consider buying G1 Therapeutics options at the current volatility level of 305.47%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
GTHX |
Purchasing G1 Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" GTHX calls. Remember, the seller must deliver G1 Therapeutics stock to the call owner when a call is exercised.
G1 Therapeutics Option Chain
When G1 Therapeutics' strike price is surpassing the current stock price, the option contract against G1 Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
G1 Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on GTHX. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for GTHX. It also shows strike prices and maturity days for a G1 Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Delta | Gamma | Open Int | Expiration | Current Spread | Last Price | |||
Call | 2024-04-19 CALL at $1.5 | 0.9563 | 0.0287 | 0 | 2024-04-19 | 0.5 - 5.0 | 1.4 | In |
Call | 2024-04-19 CALL at $3.5 | 0.7991 | 0.275 | 158 | 2024-04-19 | 0.5 - 0.8 | 0.8 | In |
Call | 2024-04-19 CALL at $4.0 | 0.922 | 1.1755 | 178 | 2024-04-19 | 0.1 - 0.25 | 0.35 | In |
Call | 2024-04-19 CALL at $5.0 | 0.1517 | 0.345 | 12834 | 2024-04-19 | 0.0 - 0.65 | 0.05 | Out |
Put | 2024-04-19 PUT at $4.0 | -0.2667 | 1.1085 | 42 | 2024-04-19 | 0.0 - 0.1 | 0.05 | Out |
Put | 2024-04-19 PUT at $4.5 | -0.6733 | 0.5936 | 5 | 2024-04-19 | 0.25 - 0.45 | 0.3 | In |
Put | 2024-04-19 PUT at $5.0 | -0.7343 | 0.324 | 1815 | 2024-04-19 | 0.75 - 1.2 | 0.43 | In |
G1 Therapeutics Total Stockholder Equity Over Time
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Total Stockholder Equity |
| Timeline |
G1 Therapeutics Common Stock Shares Outstanding Over Time
The total number of shares of a company's common stock that are currently owned by all its shareholders. Common Stock Shares Outstanding |
| Timeline |
GTHX Total Stockholder Equity
Total Stockholder Equity |
|
Be your own money manager
Our tools can tell you how much better you can do entering a position in G1 Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
G1 Therapeutics Corporate Directors
G1 Therapeutics corporate directors refer to members of a G1 Therapeutics board of directors. The board of directors generally takes responsibility for the G1 Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of G1 Therapeutics' board members must vote for the resolution. The G1 Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Andrew Witty | Director | Profile | |
| Glenn Muir | Independent Director | Profile | |
| Garry Nicholson | Independent Director | Profile | |
| Tyrell Rivers | Independent Director | Profile |
Already Invested in G1 Therapeutics?
The danger of trading G1 Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of G1 Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than G1 Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile G1 Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether G1 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of G1 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of G1 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on G1 Therapeutics Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in G1 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for GTHX Stock analysis
When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know GTHX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 1.595 | Quarterly Revenue Growth 0.451 | Return On Assets (0.16) | Return On Equity (0.92) |
The market value of G1 Therapeutics is measured differently than its book value, which is the value of GTHX that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.